Metraipolis › archive › dc_8cbbf027ab48

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk… — Europe PMC PMID:38451304

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38451304
DOI
10.1093/schbul/sbae011
License (as archived)
solo-consultazione
Archived
2026-10-08T00:35:13.305Z
SHA-256 of the archived text
6918667c02cce49ae65ada73de34bf41c43be460eeb83d5c181d77aff8803d14
Stable URL of this page
https://metraipolis.com/documento/dc_8cbbf027ab48

How to cite

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk… — Europe PMC PMID:38451304 — Europe PMC (en), https://europepmc.org/article/MED/38451304 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8cbbf027ab48 (Metraipolis archive dc_8cbbf027ab48, sha256 6918667c02cce49ae65ada73de34bf41c43be460eeb83d5c181d77aff8803d14)
BibTeX
@misc{dc8cbbf027ab48,
  title = {Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk… — Europe PMC PMID:38451304},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38451304},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8cbbf027ab48; sha256 6918667c02cce49ae65ada73de34bf41c43be460eeb83d5c181d77aff8803d14},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/38451304. Agents can read the archived copy with the MCP tool read_document.